ACR Appropriateness Criterias® Radiation Therapy for Small-Cell Lung Cancer

被引:12
作者
Kong, Feng-Ming [1 ]
Lally, Brian E. [4 ]
Chang, Joe Yujiao [5 ]
Chetty, Indrin J. [2 ]
Decker, Roy H. [6 ]
Ginsburg, Mark E. [7 ]
Kestin, Larry L. [3 ]
Langer, Corey J. [9 ]
Movsas, Benjamin [2 ]
Videtic, Gregory M. M. [10 ]
Willers, Henning [11 ]
Rosenzweig, Kenneth E. [8 ]
机构
[1] Univ Michigan, Ann Arbor Veteran Affairs Med Ctr, Ann Arbor, MI 48109 USA
[2] Henry Ford Hlth Syst, Detroit, MI USA
[3] 21st Century Oncol Michigan, Farmington Hills, MI USA
[4] Univ Miami, Dept Radiat Oncol, Miami, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Yale Univ, Sch Med, New Haven, CT USA
[7] Columbia Univ, Soc Thorac Surg, New York, NY USA
[8] Mt Sinai Sch Med, New York, NY USA
[9] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[10] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[11] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2013年 / 36卷 / 02期
关键词
small cell lung cancer; radiation therapy; appropriateness criteria; PROPHYLACTIC CRANIAL IRRADIATION; COMBINED-MODALITY TREATMENT; LEUKEMIA GROUP-B; PHASE-III TRIAL; RANDOMIZED CLINICAL-TRIAL; COUNCIL COMPARATIVE TRIAL; CISPLATIN PLUS ETOPOSIDE; THORACIC RADIOTHERAPY; COMBINATION CHEMOTHERAPY; ORAL ETOPOSIDE;
D O I
10.1097/COC.0b013e31827e5523
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The current standard of care for small cell lung cancer is combined-modality therapy, including the use of chemotherapy, surgery (in selected cases of limited stage of disease), and radiation therapy. This review will focus on the role, dose fractionation, technology and timing of thoracic radiation, and the role and dose regimen of prophylactic cranial irradiation for both limited and extensive stage of diseases. Consensus recommendation from experts is summarized in the tables for 2 typical case scenarios. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
引用
收藏
页码:206 / 213
页数:8
相关论文
共 64 条
[1]  
[Anonymous], J CLIN ONCOL S16
[2]  
[Anonymous], NCCN CLIN PRACT GUID
[3]   PROPHYLACTIC CRANIAL IRRADIATION FOR PATIENTS WITH SMALL-CELL LUNG-CANCER IN COMPLETE REMISSION [J].
ARRIAGADA, R ;
LECHEVALIER, T ;
BORIE, F ;
RIVIERE, A ;
CHOMY, P ;
MONNET, I ;
TARDIVON, A ;
VIADER, F ;
TARAYRE, M ;
BENHAMOU, S .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (03) :183-190
[4]   Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].
Aupérin, A ;
Arriagada, R ;
Pignon, JP ;
Le Péchoux, C ;
Gregor, A ;
Stephens, RJ ;
Kristjansen, PEG ;
Johnson, BE ;
Ueoka, H ;
Wagner, H ;
Aisner, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484
[5]   70 GY thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 [J].
Bogart, JA ;
Herndon, JE ;
Lyss, AP ;
Watson, D ;
Miller, AA ;
Lee, ME ;
Turrisi, AT ;
Green, MR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (02) :460-468
[6]   Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma [J].
Bonner, JA ;
Sloan, JA ;
Shanahan, TG ;
Brooks, BJ ;
Marks, RS ;
Krook, JE ;
Gerstner, JB ;
Maksymiuk, A ;
Levitt, R ;
Mailliard, JA ;
Tazelaar, HD ;
Hillman, S ;
Jett, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2681-2691
[7]   Positron emission tomography in limited-stage small-cell lung cancer: A prospective study [J].
Bradley, JD ;
Dehdashti, F ;
Mintun, MA ;
Govindan, R ;
Trinkaus, K ;
Siegel, BA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3248-3254
[8]  
COHEN MH, 1979, CANCER TREAT REP, V63, P163
[9]   Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].
De Ruysscher, D ;
Pijls-Johannesma, M ;
Bentzen, SM ;
Minken, A ;
Wanders, R ;
Lutgens, L ;
Hochstenbag, M ;
Boersma, L ;
Wouters, B ;
Lammering, G ;
Vansteenkiste, J ;
Lambin, P .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063
[10]  
EINHORN LH, 1978, SEMIN ONCOL, V5, P309